178 related articles for article (PubMed ID: 23958920)
1. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
Spijkers-Hagelstein JA; Pinhanços SS; Schneider P; Pieters R; Stam RW
Leukemia; 2014 Apr; 28(4):761-9. PubMed ID: 23958920
[TBL] [Abstract][Full Text] [Related]
2. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
3. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
[TBL] [Abstract][Full Text] [Related]
4. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
5. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
6. Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
Beesley AH; Rampellini JL; Palmer ML; Heng JY; Samuels AL; Firth MJ; Ford J; Kees UR
Mol Cancer; 2010 Oct; 9():284. PubMed ID: 20979663
[TBL] [Abstract][Full Text] [Related]
7. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
[TBL] [Abstract][Full Text] [Related]
9. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
[TBL] [Abstract][Full Text] [Related]
10. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
Ramakers-van Woerden NL; Beverloo HB; Veerman AJ; Camitta BM; Loonen AH; van Wering ER; Slater RM; Harbott J; den Boer ML; Ludwig WD; Haas OA; Janka-Schaub GE; Pieters R
Leukemia; 2004 Mar; 18(3):521-9. PubMed ID: 14712291
[TBL] [Abstract][Full Text] [Related]
12. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract][Full Text] [Related]
13. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
14. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
[TBL] [Abstract][Full Text] [Related]
15. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
16. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Rahmatallah Y; Masoudi-Nejad A
Mol Med; 2019 Aug; 25(1):36. PubMed ID: 31370801
[TBL] [Abstract][Full Text] [Related]
17. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
18. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
19. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]